Medications for the treatment of obesity - 31/01/23
This article has been published in an issue click here to access
Summary |
After several years with no real therapeutic alternatives, the management of obesity is entering a new era with the development of new surgical and endoscopic bariatric techniques, digital therapeutics and the arrival of new classes of drugs. New medication treatments aim to reduce food intake, targeting the hypothalamic regulation of food intake and satiety. The mechanism of their action remains poorly understood but, combines weight reduction and amelioration of cardiometabolic risk factors with a favorable benefit-risk balance and known side effects, mainly digestive. The future will tell us how these drugs will find their place in the management of this chronic disease that is obesity.
El texto completo de este artículo está disponible en PDF.Keywords : Suspensive pharmacotherapy, GLP1 receptor agonists, Glucagon intestinal peptide (GIP), Hypothalamus, Leptin-melanocortin Leptin
Esquema
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?